Shikonin inhibits Vascular Smooth Muscle Cell Phenotypic Modulation and attenuates Neointimal Hyperplasia
Drug Research · 15.09.2026
DOI: 10.1055/a-2945-2736 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Research, erschienen am 15.09.2026. Verfasst von Ankan Sarkar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Panjab University, University Institute of Pharmaceutical Sciences, Chandigarh, India, Chandigarh. Die Arbeit nennt 53 Literaturangaben. Gefördert von: DST SERB-, DBT Ramalingaswami Re-entry Fellowship.
Abstract (Originalsprache)
Purpose
Enhanced glycolytic activity drives vascular smooth muscle cell proliferation and migration. Pyruvate kinase M2, a key glycolytic enzyme, modulates cancer cell proliferation. Shikonin, an inhibitor of pyruvate kinase M2, exerts anti-proliferative effects on cancer cells; still, its involvement in vascular smooth muscle cell proliferation and neointimal hyperplasia is not established. We investigated the effects of shikonin on platelet-derived growth factor-BB–induced changes in vascular smooth muscle cell function and neointimal hyperplasia.
Methods
Murine aortic vascular smooth muscle cells were pretreated with shikonin and stimulated with platelet-derived growth factor-BB. Wire injury of the carotid artery was performed in C57Bl/J6 mice to induce neointimal hyperplasia.
Results
Our study observes a marked upregulation of pyruvate kinase M2 in platelet-derived growth factor-BB stimulated vascular smooth muscle cells. Shikonin inhibited pyruvate kinase M2 expression and effectively reduced platelet-derived growth factor-BB–induced vascular smooth muscle cell proliferation and migration and also favoured the contractile vascular smooth muscle cell phenotype. Expression of matrix metalloproteinase-2 and interleukin-6 messenger RNAs was significantly lower in shikonin-treated vascular smooth muscle cells as compared to platelet-derived growth factor-BB–treated control. Pyruvate kinase M2 translocated to the mitochondria and pyruvate kinase M2 inhibition via shikonin promoted mitochondrial reactive oxygen species levels, increased oxidative stress and induced vascular smooth muscle cell apoptosis. Perivascular application of shikonin suppressed neointimal hyperplasia.
Conclusion
Our findings indicate that shikonin suppresses vascular smooth muscle cell proliferation and migration, thereby limiting neointimal hyperplasia and potentially serving as a novel therapeutic strategy for atherosclerosis and restenosis.
Autor:innen und Institutionen
- Panjab University, University Institute of Pharmaceutical Sciences, Chandigarh, India, Chandigarh.
- National Institute of Pharmaceutical Education and Research, Department of Pharmacology and Toxicology, PB, India, Sahibzada Ajit Singh Nagar.
ORCID-Profile: Manish Jain
Förderung
- DST SERB-
- DBT Ramalingaswami Re-entry Fellowship
Zitieren
APA
Sarkar, A., Ahmed, S., Singh, M., Sharma, S. S., Chopra, K., & Jain, M. (2026). Shikonin inhibits Vascular Smooth Muscle Cell Phenotypic Modulation and attenuates Neointimal Hyperplasia. Drug Research. https://doi.org/10.1055/a-2945-2736
Vancouver
Sarkar A, Ahmed S, Singh M, Sharma SS, Chopra K, Jain M. Shikonin inhibits Vascular Smooth Muscle Cell Phenotypic Modulation and attenuates Neointimal Hyperplasia. Drug Research. 2026. doi:10.1055/a-2945-2736
BibTeX
@article{Sarkar2026,
author = {Sarkar, Ankan and Ahmed, Sakeel and Singh, Monika and Sharma, Shyam Sunder and Chopra, Kanwaljit and Jain, Manish},
title = {Shikonin inhibits Vascular Smooth Muscle Cell Phenotypic Modulation and attenuates Neointimal Hyperplasia},
journal = {Drug Research},
year = {2026},
doi = {10.1055/a-2945-2736}
}
EUVIMED